Granted Patent
B2
US 12,697,355 · App. 17/905,742 · Granted Aug 4, 2026
Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
Assignee:
Mesoblast International Sárl
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to method of treating or preventing an inflammatory lung disease in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs).
Claims (19)
1 . A method of treating an inflammatory lung disease in a human subject in need thereof, the method comprising administering to the subject a composition comprising a population of culture expanded mesenchymal lineage precursor or stem cells (MLPSCs), wherein the subject has a circulating C-reactive protein (CRP) level of ≥2 mg/L, wherein the inflammatory lung disease is selected from the group consisting of Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension (PAH), and asthma, and wherein the subject has an improvement in one or more of the following after treatment:
Forced expiratory volume in one second (FEV1);
Forced vital capacity (FVC);
FEV1/FVC and;
6 minute walk test.
2 . The method of claim 1 , wherein the MLPSCs are culture expanded from an intermediate cryopreserved MLPSCs population.
3 . The method of claim 1 , wherein the composition is administered intravenously.
4 . The method of claim 1 , wherein the MLPSCs are mesenchymal stem cells (MSCs).
5 . The method of claim 1 , which comprises administering between 1×10 7 and 2×10 8 cells per dose, wherein a dose is administered at baseline followed by 3 subsequent monthly doses over 90 days.
6 . The method of claim 1 , which comprises administering about 1×10 8 cells per dose, wherein a dose is administered at baseline followed by 3 subsequent monthly doses over 90 days.
7 . The method of claim 1 , wherein the subject has an FEV1 change from baseline of at least 0.02, within 120 days of treatment.
8 . The method of claim 1 , wherein the subject has an FEV1 change from baseline of at least 0.05, within 120 days of treatment.
9 . The method of claim 1 , wherein the subject has an FVC change from baseline of at least 0.05, within 120 days of treatment.
10 . The method of claim 1 , wherein the subject has an FVC change from baseline of at least 0.1, within 120 days of treatment.
11 . The method of claim 1 , wherein the subject has an FEV1/FVC change from baseline of at least 0.01, within 120 days of treatment.
12 . The method of claim 1 , wherein the subject has an FEV1/FVC change from baseline of at least 0.015, within 120 days of treatment.
13 . The method of claim 1 , wherein the subject shows an improvement in the 6 minute walk test of at least 40 meters, within 60 days or within 120 days of treatment.
14 . The method of claim 1 , wherein the subject shows an improvement in the 6 minute walk test of at least 50 meters, within 60 days or within 120 days of treatment.
15 . The method of claim 1 , wherein the composition comprises greater than 6.68×10 6 viable cells/mL.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 14, 2023
From: ITESCU, SILVIU
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 062976/0276 →
Priority Claims (1)
AU 2020900685
· Mar 5, 2020
· national
Continuity (1)
Related Publication
20230293589A1
· Sep 21, 2023
References Cited (319)
US 5486359A
· Caplan et al.
· 1996
[cited by applicant]
US 5736396A
· Bruder et al.
· 1998
[cited by applicant]
US 5827740A
· Pittenger
· 1998
[cited by applicant]
US 6030836A
· Thiede et al.
· 2000
[cited by applicant]
US 6328960B1
· Mcintosh et al.
· 2001
[cited by applicant]
US 6368636B1
· McIntosh et al.
· 2002
[cited by applicant]
US 6387369B1
· Pittenger et al.
· 2002
[cited by applicant]
US 6685936B2
· Mcintosh et al.
· 2004
[cited by applicant]
US 6797269B2
· Mosca et al.
· 2004
[cited by applicant]
US 6875430B2
· McIntosh et al.
· 2005
[cited by applicant]
US 6936281B2
· Seshi
· 2005
[cited by applicant]
US 6974571B2
· Prockop et al.
· 2005
[cited by applicant]
US 7364900B2
· Black et al.
· 2008
[cited by applicant]
US 7968088B2
· Honmou et al.
· 2011
[cited by applicant]
US 8105580B2
· Fraser et al.
· 2012
[cited by applicant]
US 8142773B2
· Aslan et al.
· 2012
[cited by applicant]
US 8147824B2
· Maziarz et al.
· 2012
[cited by applicant]
US 8440177B2
· González De La Peña et al.
· 2013
[cited by applicant]
US 8486695B2
· Danilkovitch et al.
· 2013
[cited by applicant]
US 8637004B2
· Danilkovich et al.
· 2014
[cited by applicant]
US 9301978B2
· Itescu et al.
· 2016
[cited by applicant]
US 9694035B2
· Aggarwal et al.
· 2017
[cited by applicant]
US 9828586B2
· Tom et al.
· 2017
[cited by applicant]
US 9888679B2
· Ghosh
· 2018
[cited by applicant]
US 9943547B2
· Aggarwal et al.
· 2018
[cited by applicant]
US 9963678B2
· Tom et al.
· 2018
[cited by applicant]
US 20020044923A1
· Mosca et al.
· 2002
[cited by applicant]
US 20030118567A1
· Stewart
· 2003
[cited by applicant]
US 20040018174A1
· Palasis
· 2004
[cited by applicant]
US 20040033214A1
· Young et al.
· 2004
[cited by applicant]
US 20040166097A1
· Prockop et al.
· 2004
[cited by applicant]
US 20050239897A1
· Pittenger et al.
· 2005
[cited by applicant]
US 20070253931A1
· Varney et al.
· 2007
[cited by applicant]
US 20070258963A1
· Danilkovitch et al.
· 2007
[cited by applicant]
US 20080095749A1
· Aggarwal et al.
· 2008
[cited by applicant]
US 20080132450A1
· Lee
· 2008
[cited by applicant]
US 20080213227A1
· Aggarwal et al.
· 2008
[cited by applicant]
US 20090169522A1
· Danilkovitch et al.
· 2009
[cited by applicant]
US 20090180997A1
· Pittenger et al.
· 2009
[cited by applicant]
US 20090208463A1
· Pittenger et al.
· 2009
[cited by applicant]
US 20090214487A1
· Varney et al.
· 2009
[cited by applicant]
US 20090220464A1
· Aggarwal et al.
· 2009
[cited by applicant]
US 20090324609A1
· Lodie et al.
· 2009
[cited by applicant]
US 20100040583A1
· Falanga
· 2010
[cited by applicant]
US 20100172885A1
· Pittenger et al.
· 2010
[cited by applicant]
US 20100330048A1
· Aggarwal et al.
· 2010
[cited by applicant]
US 20110027238A1
· Aggarwal et al.
· 2011
[cited by applicant]
US 20110142807A1
· Pittenger et al.
· 2011
[cited by applicant]
US 20110189768A1
· Danilkovitch et al.
· 2011
[cited by applicant]
US 20110311496A1
· Pittenger et al.
· 2011
[cited by applicant]
US 20110318314A1
· Aggarwal et al.
· 2011
[cited by applicant]
US 20110318315A1
· Aggarwal et al.
· 2011
[cited by applicant]
US 20120052049A1
· Woods et al.
· 2012
[cited by applicant]
US 20120087933A1
· Tom et al.
· 2012
[cited by applicant]
US 20120201791A1
· Yoo
· 2012
[cited by applicant]
US 20120269774A1
· Ichim et al.
· 2012
[cited by applicant]
US 20130259841A1
· Danilkovitch et al.
· 2013
[cited by applicant]
US 20140105872A1
· Danilkovitch et al.
· 2014
[cited by applicant]
US 20140134140A1
· Caplan
· 2014
[cited by applicant]
US 20140248244A1
· Danilkovitch et al.
· 2014
[cited by applicant]
US 20140328807A1
· Aggarwal et al.
· 2014
[cited by applicant]
US 20150004693A1
· Danilkovitch et al.
· 2015
[cited by applicant]
US 20150272997A1
· Aggarwal et al.
· 2015
[cited by applicant]
US 20160199413A1
· Simonson et al.
· 2016
[cited by applicant]
US 20160271180A1
· Yamashita
· 2016
[cited by applicant]
US 20180008642A1
· Danilkovitch et al.
· 2018
[cited by applicant]
US 20180037867A1
· Simmons et al.
· 2018
[cited by applicant]
US 20180087032A1
· Danilkovitch et al.
· 2018
[cited by applicant]
US 20200197444A1
· Danilkovich et al.
· 2020
[cited by applicant]
US 20200325450A1
· Itescu et al.
· 2020
[cited by applicant]
US 20210169940A1
· Bernard
· 2021
[cited by applicant]
US 20220079991A1
· Itescu
· 2022
[cited by applicant]
US 20220143097A1
· Itescu et al.
· 2022
[cited by applicant]
US 20220160776A1
· Itescu et al.
· 2022
[cited by applicant]
US 20220226386A1
· Itescu
· 2022
[cited by applicant]
US 20220275337A1
· Devine et al.
· 2022
[cited by applicant]
US 20230076630A1
· Aggarwal et al.
· 2023
[cited by applicant]
US 20230089901A1
· Danilkovich et al.
· 2023
[cited by applicant]
US 20230097931A1
· Itescu
· 2023
[cited by applicant]
US 20230104108A1
· Itescu
· 2023
[cited by applicant]
US 20230165904A1
· Itescu
· 2023
[cited by applicant]
US 20230172991A1
· Itescu
· 2023
[cited by applicant]
US 20230220349A1
· Simmons
· 2023
[cited by applicant]
US 20230293590A1
· Itescu
· 2023
[cited by applicant]
US 20230346846A1
· Itescu et al.
· 2023
[cited by applicant]
US 20230398154A1
· Itescu et al.
· 2023
[cited by applicant]
US 20240041934A1
· Itescu et al.
· 2024
[cited by applicant]
US 20240091266A1
· Itescu et al.
· 2024
[cited by applicant]
US 20240197787A1
· Itescu et al.
· 2024
[cited by applicant]
US 20240207323A1
· Itescu et al.
· 2024
[cited by applicant]
US 20240301356A1
· Danilkovich et al.
· 2024
[cited by applicant]
US 20250032552A1
· Itescu
· 2025
[cited by applicant]
US 20250090589A1
· Itescu et al.
· 2025
[cited by applicant]
US 20250129337A1
· Simmons et al.
· 2025
[cited by applicant]
US 20250161365A1
· Itescu et al.
· 2025
[cited by applicant]
US 20250312379A1
· Danilkovich et al.
· 2025
[cited by applicant]
US 20250319428A1
· Horst et al.
· 2025
[cited by applicant]
US 20260035666A1
· Tom et al.
· 2026
[cited by applicant]
US 20260069635A1
· Itescu
· 2026
[cited by applicant]
CN 101626772A
· 2010
[cited by applicant]
CN 105796598A
· 2016
[cited by applicant]
CN 111297899A
· 2020
[cited by applicant]
CN 112522191A
· 2021
[cited by applicant]
EP 2476751A1
· 2012
[cited by applicant]
EP 3583945A1
· 2019
[cited by applicant]
ES 2385450T3
· 2012
[cited by applicant]
WO WO9951247A1
· 1999
[cited by applicant]
WO WO0126470A1
· 2001
[cited by applicant]
WO WO2004003164A2
· 2004
[cited by applicant]
WO WO2005093044A1
· 2005
[cited by applicant]
WO WO2006112365A1
· 2006
[cited by applicant]
WO WO2007087139A2
· 2007
[cited by applicant]
WO WO2008116157A2
· 2008
[cited by applicant]
WO WO2009028870A2
· 2009
[cited by applicant]
WO WO2010019886A1
· 2010
[cited by applicant]
WO WO2012048093A2
· 2012
[cited by applicant]
WO WO2015016761A2
· 2015
[cited by applicant]
WO WO2015077624A1
· 2015
[cited by applicant]
WO WO2016086020A1
· 2016
[cited by applicant]
WO WO2016102601A1
· 2016
[cited by applicant]
WO WO2016139340A1
· 2016
[cited by applicant]
WO WO2018151046A1
· 2018
[cited by applicant]
WO WO2018202853A1
· 2018
[cited by applicant]
WO WO2019051623A1
· 2019
[cited by applicant]
WO WO2019102268A1
· 2019
[cited by applicant]
WO WO2020141473A1
· 2020
[cited by applicant]
WO WO2020141483A1
· 2020
[cited by applicant]
WO WO2020157660A1
· 2020
[cited by applicant]
WO WO2020234450A1
· 2020
[cited by applicant]
WO WO2021007180A1
· 2021
[cited by applicant]
WO WO2021024207A1
· 2021
[cited by applicant]
WO WO2021165420A1
· 2021
[cited by applicant]
WO WO2021176001A1
· 2021
[cited by applicant]
WO WO2021180850A1
· 2021
[cited by applicant]
WO WO2021180851A1
· 2021
[cited by applicant]
WO WO2021198454A1
· 2021
[cited by applicant]
WO WO2021222389A1
· 2021
[cited by applicant]
WO WO2022034467A1
· 2022
[cited by applicant]
WO WO2022034506A1
· 2022
[cited by applicant]
WO WO2022132986A1
· 2022
[cited by applicant]
WO WO2022159731A1
· 2022
[cited by applicant]
WO WO2023238074A1
· 2023
[cited by applicant]
Kebriaei P, Hayes J, Daly A, Uberti J, Skerrett D, Shpall E, Martin PJ. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host…
[cited by examiner]
Marquez-Curtis LA, Janowska-Wieczorek A, McGann LE, Elliott JA. Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects. Cryobiology. Oct. 2015;71(2):181-97. doi: 10.101…
[cited by examiner]
Sun Z, Li F, Zhou X, Chung KF, Wang W, Wang J. Stem cell therapies for chronic obstructive pulmonary disease: current status of pre-clinical studies and clinical trials. J Thorac Dis. Feb. 2018;10(2):1084-1098. doi: 10.…
[cited by examiner]
Zhao R, Su Z, Wu J, Ji HL. Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis. Oncotarget. May 2, 2017;8(18):30511-30523. doi: 10.18632/oncotarget.15426. PMID: 2843062…
[cited by examiner]
Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. Jun. 2013;143(6):1590-1598. doi: 10.1378/chest.12-2094. PMID: 23172272; P…
[cited by examiner]
Weiss, D.J., et al., “A Placebo-controlled, randomized trial of mesenchymal stem cells in COPD,” Chest 143(6):1590-1598, Elsevier, Netherlands (Jun. 2013).
[cited by applicant]
Simonson, O.E., et al., “In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome,” Stem Cells Transl Med 4(10):1199-213, Wiley, United States (Aug. 2015).
[cited by applicant]
Matthay, M.A., et al., “Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial,” Lancet Respir Med 7(2):154-162, …
[cited by applicant]
Liu, Y., et al., “Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019” medRxiv, Cold Spring Harbor Laboratory, United States (Feb. 2020).
[cited by applicant]
Leng, Z., et al., “Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia,” Aging and Disease 11(2):216-228, JKL International on behalf of the International Society on A…
[cited by applicant]
Balnis, J., et al., “Unique Inflammatory Profile is Associated With Higher SARS-CoV-2 Acute Respiratory Distress Syndrome (ARDS) Mortality,” 17 pages, (Aug. 2020).
[cited by applicant]
Bode, S., et al., “Recent Advances in the Diagnosis and Treatment of Hemophagocytic Lymphohistiocytosis,” Arthritis Research & Therapy 14(3):213, 1-12, BioMed Central, United Kingdom (Jun. 2012).
[cited by applicant]
Callahan, V., et al., “The Pro-inflammatory Chemokines CXCL9, CXCL 10 and CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-dependent Manner,” Viruses 13(6):1062, 1-18, MDPI, Switzerland (Jun. 2021).
[cited by applicant]
Chen, X., et al., “The Interaction Between Mesenchymal Stem Cells and Steroids During Inflammation,” Cell Death & Disease 5(1):e1009, 1-12, Nature Pub. Group, United Kingdom (Jan. 2014).
[cited by applicant]
Chua, R.L., “COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis,” Nature Biotechnology 38(8):970-979, Nature America Publishing, United States (Aug. 2020).
[cited by applicant]
Crayne, C.B., et al., “The Immunology of Macrophage Activation Syndrome,” Frontiers in Immunology 10:119, 1-11, Frontiers Research Foundation, Switzerland (Feb. 2019).
[cited by applicant]
Humblet-Baron, S., et al., “IFN-γ and CD25 Drive Distinct Pathologic Features During Hemophagocytic Lymphohistiocytosis,” The Journal of Allergy and Clinical Immunology 143(6):2215-2226.e7, Mosby, United States (2018).
[cited by applicant]
Kaneko, N., et al., “Expansion of Cytotoxic CD4+ T Cells in the Lungs in Severe Covid-19,” medRxiv 2021.03.23.21253885, 1-46, Cold Spring Harbor Laboratory, United States (Mar. 2021).
[cited by applicant]
Mathew, D., et al., “Deep Immune Profiling of Covid-19 Patients Reveals Distinct Immunotypes With Therapeutic Implications,” Science 369(6508):eabc8511, 1-18, American Association for the Advancement of Science, United …
[cited by applicant]
Meckiff, B.J., et al., “Single-cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4+ T Cells,” bioRxiv 2020.06.12.148916, 1-37, Cold Spring Harbor Laboratory, United States (Jun. 2020).
[cited by applicant]
Mehta, P., “COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression,” Lancet 395(10229):1033-1034, Elsevier, United kingdom (Mar. 2020).
[cited by applicant]
Meizlish, M.L., “A Neutrophil Activation Signature Predicts Critical Illness and Mortality in COVID-19,” Blood Advances 5(5):1164-1177, American Society of Hematology, United States (Mar. 2021).
[cited by applicant]
Moderbacher, C.R., et al., “Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity,” Cell 183(4):996-1012.e19, Cell Press, United States (Nov. 2020).
[cited by applicant]
Seguin, A., et al., “Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis,” Chest 149(5):1294-1301, Elsevier, United States (May 2016).
[cited by applicant]
Sette, A and Crotty, S., “Adaptive Immunity to SARS-CoV-2 and COVID-19,” Cell 184(4):861-880, Cell Press, United States (Feb. 2021).
[cited by applicant]
Stehlik, P., “Repeat Testing for SARS-CoV-2: Persistence of Viral RNA is Common, and Clearance is Slower in Older People,” The Medical Journal of Australia 214(10):468-470, Australian Medical Publishing Co., Australia (…
[cited by applicant]
Yan, Y., et al., “CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention,” Frontiers in Cell and Developmental Biology 7:212, 1-13, Frontiers Media S.A., Switzerland (Oct…
[cited by applicant]
Zhou, B., “Utility of Ferritin, Procalcitonin, and C-reactive Protein in Severe Patients with 2019 Novel Coronavirus Disease,” Research Square, 1-12, Springer Nature, Germany (Mar. 2020).
[cited by applicant]
Zhou, Y., et al., “Pathogenic T-cells and Inflammatory Monocytes Incite Inflammatory Storms in Severe COVID-19 Patients,” National Science Review 7(6):998-1002, Oxford University Press, United Kingdom (Jun. 2020).
[cited by applicant]
Zhu, L., et al., “Cellular Metabolism and Macrophage Functional Polarization,” International Reviews of Immunology 34(1):82-100, Informa Healthcare, United Kingdom (Jan. 2015).
[cited by applicant]
Afzali, B., et al., “The Role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease,” Clinical and Experimental Immunology 148(1):32-46, Blackwell Scientific Publicati…
[cited by applicant]
Aggarwal, S. and Pittenger, M.F., “Human Mesenchymal Stem Cells Modulate Allogeneic Immune Cell Responses,” Blood 105(4):1815-1822, American Society of Hematology, United States (Feb. 2005).
[cited by applicant]
American Association for Respiratory Care: AARC Clinical Practice Guideline: Spirometry, Respiratory Care 41:629-638 (1996 Update).
[cited by applicant]
Anonymous: “Athersys Provides Update on One-Year ARDS Study Data,” News Release 1-5 pages (Jan. 2020).
[cited by applicant]
Anonymous: “Mesoblast to evaluate anti-inflammatory cell therapy remestemcel-L for treatment of Covid-19 lung disease,” 3 pages (2020).
[cited by applicant]
Atluri, S., et al., “Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use,” Pain Physician 23(2):E71-E83 America…
[cited by applicant]
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories., “ATS Statement: Guidelines for the Six-minute Walk Test,” American Journal of Respiratory and Critical Care Medicine 166(1):111-117, …
[cited by applicant]
Barry, F.P and Murphy, J.M., “Mesenchymal Stem Cells: Clinical Application and Biological Characterization,” International Journal of Biochemistry & Cell Biology 36:568-584, Elsevier, Netherlands (Apr. 2004).
[cited by applicant]
Barry, F.P., et al., “Biology And Clinical Applications of Mesenchymal Stem Cells, ” Birth Defects Research Part C: Embryo Today 69(3):250-256, Wiley Periodicals, Inc., United States (Aug. 2003).
[cited by applicant]
Bartholomew, A., et al., “Mesenchymal Stem Cells Suppress Lymphocyte Proliferation In Vitro And Prolong Skin Graft Survival In Vivo,” Experimental Hematology 30(1):42-48, Elsevier Science Inc., Netherlands (Jan. 2002).
[cited by applicant]
Bobis, S., et al., “Mesenchymal Stem Cells: Characteristics and Clinical Applications,” Folia Histochemica ET Cytobiologica 44(4):215-230, Polish Histochemical and Cytochemical Society at VM Media, Poland (2006).
[cited by applicant]
Borzone, G., et al., “Bleomycin-induced Chronic Lung Damage Does Not Resemble Human Idiopathic Pulmonary Fibrosis,” American Journal of Respiratory and Critical Care Medicine 163(7):1648-1653, American Thoracic Society,…
[cited by applicant]
Boston Scientific Corporation, “Boston Scientific and Osiris Therapeutics Announce Stem Cell Alliance,” accessed at URL:[www.ptca.org/press_rel/20030311pr_boston.html] on Apr. 12, 2023, 2 pages (Mar. 11, 2003).
[cited by applicant]
Boucher, R.C, “New Concepts of the Pathogenesis of Cystic Fibrosis Lung Disease,” The European Respiratory Journal 23(1):146-158, European Respiratory Society, England (Jan. 2004).
[cited by applicant]
Bowden, D.H, “Unraveling Pulmonary Fibrosis: the Bleomycin Model,” Laboratory Investigation 50(5):487-488, Nature Publishing Group, United States (May 1984).
[cited by applicant]
Brass, D.M., et al., “Reduced Tumor Necrosis Factor-α and transforming Growth Factor-β1 Expression in the Lungs of Inbred Mice that Fail to Develop Fibroproliferative Lesions Consequent to Asbestos Exposure,” American J…
[cited by applicant]
Burand, A.J., et al., “Function of Cryopreserved MSCs with and without IFN-γ pre-licensing is Context Dependent,” Stem Cells 35(5):1437-1439, Wiley, United States (Nov. 2016).
[cited by applicant]
Chen, J., et al., “Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment,” Engineering 6(10):1153-1161,…
[cited by applicant]
Collier, M., et al., “Understanding Wound Inflammation,” Nursing Times 99(25:63-64, Macmillian Journals, England (Jun. 2003).
[cited by applicant]
Conese, M., et al., “Stem Cells and Cystic Fibrosis,” Cystic Fibrosis 5(3):141-143, Elsevier, Netherlands (Aug. 2006).
[cited by applicant]
Czitrom, A.A., “The Immune Response: The Afferent Arm,” Clinical Orthopaedics and Related Research (326):11-24, Wolters Kluwer, United States (May 1996).
[cited by applicant]
De Miguel, M.P., et al., “Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications,” Current Molecular Medicine 12(5):574-591, Bentham Science Publishers, Netherlands (Jun. 2012).
[cited by applicant]
Deans, R.J and Moseley, A.B, “Mesenchymal Stem Cells: Biology and Potential Clinical Uses,” Experimental Hematology 28(8):875-884, Elsevier Science Inc, Netherlands (Aug. 2000).
[cited by applicant]
Devine, S.M., et al., “Mesenchymal Stem Cells Distribute To a Wide Range of Tissues Following Systemic Infusion into Nonhuman Primates,” Blood 101(8):2999-3001, American Society of Hematology, United States (Apr. 2003).
[cited by applicant]
Di Nicola, M., et al., “Human Bone Marrow Stromal Cells Suppress T-Lymphocyte Proliferation Induced By Cellular or Nonspecific Mitogenic Stimuli,” Blood 99(10):3838-3843, American Society of Hematology, United States (M…
[cited by applicant]
Chang, Y.S., et al., “Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats,” Cell Transplant 18(8):869-86, Sage Journals, United States (Apr. 2009).
[cited by applicant]
Fischer, U, M., et al., “Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: the Pulmonary First-pass Effect,” Stem cells and development 18(5):683-692, Mary Ann Liebert, Inc., United States (Jun. …
[cited by applicant]
Gao, J., et al., “The Dynamic in Vivo Distribution of Bone Marrow-derived Mesenchymal Stem Cells After Infusion,” Cells, Tissues, Organs 169(1):12-20, Karger, Switzerland (Apr. 2001).
[cited by applicant]
Griffin, M. D., et al.,. “Anti-donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells: What Have We Learned so Far?,” Immunology and Cell Biology 91(1):40-51, Wiley, United States (Jan. 2013).
[cited by applicant]
Gronthos, S., et al., “Molecular and Cellular Characterisation of Highly Purified Stromal Stem Cells Derived From Human Bone Marrow,” Journal of Cell Science 116(Pt 9):1827-1835, Company of Biologists, United Kingdom (M…
[cited by applicant]
Guo, Z., et al., “Biological Features of Mesenchymal Stem Cells From Human Bone Marrow,” Chinese Medical Journal 114(9):950-953, Wolters Kluwer-Medknow, China (Sep. 2001).
[cited by applicant]
Hackney, J.A., et al., “A Molecular Profile of a Hematopoietic Stem Cell Niche,” PNAS, 99(20): 13061-13066, National Academy of Science, United States (Oct. 2002).
[cited by applicant]
Horwitz, E.M., et al., “Clarification of the Nomenclature for MSC: The International Society for Cellular Therapy Position Statement,” Cytotherapy 7(5):393-395, Elsevier, United Kingdom (Jan. 2005).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2021/055483, European Patent Office, Netherlands, mailed on Jun. 8, 2021,14 pages.
[cited by applicant]
Izadpanah, R., et al., “Biologic Properties of Mesenchymal Stem Cells Derived From Bone Marrow and Adipose Tissue,” Journal of Cellular Biochemistry 99(5):1285-1297, Wiley-Liss, United States (Dec. 2006).
[cited by applicant]
Jiang, Y., et al., “Pluripotency of Mesenchymal Stem Cells Derived From Adult Marrow,” Nature, 418(6893):41-49, Nature Publishing Group, United Kingdom (Jul. 2002).
[cited by applicant]
Kassem, M., “Mesenchymal Stem Cells: Biological Characteristics and Potential Clinical Applications,” Cloning and Stem Cells 6(4):369-374, Mary Ann Liebert, Inc., United States (Dec. 2004).
[cited by applicant]
Katzenstein, A-L, A., et al., “Idiopathic Pulmonary Fibrosis; Clinical Relevance of Pathologic Classification,” Am J Respir Crit Care Med 157(4 Pt 1):1301-1315, American Thoracic Society, United States (Apr. 1998).
[cited by applicant]
Kavanagh, H. and Mahon, B.P., “Allogeneic Mesenchymal Stem Cells Prevent Allergic Airway Inflammation by Inducing Murine Regulatory T Cells,” Allergy 66: 523-531, John Wilet & Sons A/S, United States (2011).
[cited by applicant]
Kotton, D.N., et al., “Bone Marrow-derived Cells as Progenitors of Lung Alveolar Epithelium,” Development 128(24):5181-5188, Company of Biologists Limited, England (2001).
[cited by applicant]
Krause, D.S., et al., “Multi-organ, Multi-lineage Engraftment by a Single Bone Marrow-derived Stem Cell,” Cell 105(3):369-377, Cell Press, United States (May 2001).
[cited by applicant]
Krebsbach, P.H., et al., “Bone Marrow Stromal Cells: Characterization and Clinical Application,” Critical Reviews in Oral Biology and Medicine 10(2):165-181, International Association for Dental Research, United States …
[cited by applicant]
Le Blanc, K. and Ringden, O., “Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic Stem Cell Transplantation,” Biology of Blood and Marrow Transplantation 11(5):321-334, Carden Jennings Publish…
[cited by applicant]
Le Blanc, K., “Immunomodulatory Effects of Fetal and Adult Mesenchymal Stem Cells,” Cytotherapy 5(6):485-489, Elsevier, United Kingdom (2003).
[cited by applicant]
Le Blanc, K., et al., “HLA Expression and Immunologic Properties of Differentiated and Undifferentiated Mesenchymal Stem Cells,” Experimental Hematology 31(10):890-896, Elsevier Science Inc, Netherlands (Oct. 2003).
[cited by applicant]
Lindner, U., et al., “Mesenchymal Stem or Stromal Cells: Toward a Better Understanding of Their Biology?,” Transfusion Medicine and Hemotherapy 37(2):75-83, S. Karger, Switzerland (Apr. 2010).
[cited by applicant]
Lucchini, G., et al., “Platelet-lysate-expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-host Disease in a Pediatric Population,” Biology of blood and marrow transplantation 16(9)…
[cited by applicant]
Lukomska, B., et al., “Challenges and Controversies in Human Mesenchymal Stem Cell Therapy,” Stem cells international 2019: Article ID (9628536), SAGE-Hindawi Access to Research, United States (Apr. 2019).
[cited by applicant]
Mackenzie, T.C. and Flake, A.W., “Human Mesenchymal Stem Cells Persist, Demonstrate Site-specific Multipotential Differentiation, and Are Present in Sites of Wound Healing and Tissue Regeneration After Transplantation I…
[cited by applicant]
Maitra, B., et al., “Human Mesenchymal Stem Cells Support Unrelated Donor Hematopoietic Stem Cells and Suppress T-cell Activation,” Bone Marrow Transplant 33(6):597-604, Nature Publishing Group, United Kingdom (Mar. 200…
[cited by applicant]
Martire, A., et al., “Mesenchymal stem cells attenuate inflammatory processes in the heart and lung via inhibition of TNF signaling,” Basic Res Cardiol 111(5):54, Springer Berlin Heidelberg, Germany (Sep. 2016).
[cited by applicant]
Mcintosh, K. and Bartholomew, A., “Stromal Cell Modulation of The Immune System,” Graft Review 3(6):324-328, SAGE Publications, United States (2000).
[cited by applicant]
Mcnulty, K and Janes, S.M., “Stem Cells and Pulmonary Fibrosis: Cause or Cure?,” Proc Am Thorac Soc 9(3):164-171, American Thoracic Society, United States (Jul. 2012).
[cited by applicant]
Meisel, R., et al., “Human bone marrow stromal cells inhibit allogenic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation,” Immunobiology 103(12):4619-4621, The American Society of Hematolog…
[cited by applicant]
Melgar, S., et al., “Over-expression of Interleukin 10 in Mucosal T Cells of Patients With Active Ulcerative Colitis,” Clinical and Experimental Immunology 134(1):127-137, Blackwell Scientific Publications, United Kingd…
[cited by applicant]
Mesoblast Limited, “Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA For Prevention Of Gastrointestinal Bleeding In Patients With Left Ventricular Assist Devices,” investorsmedia.mesoblast.…
[cited by applicant]
Neuringer I.P., et al., “Stem Cells and Repair of Lung Injuries,” Respiratory Research, 5, 6, (Jul. 2004).
[cited by applicant]
Newman, R.E., et al., “Treatment of Inflammatory Diseases With Mesenchymal Stem Cells,” Inflammation & Allergy Drug Targets 8(2):110-123, Bentham Science Publishers, United Arab Emirates (Jun. 2009).
[cited by applicant]
Niederwieser, D., et al., “Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey,” Bone ma…
[cited by applicant]
Ortiz, L.A., et al., “Mesenchymal Stem Cell Engraftment in Lung Is Enhanced in Response to Bleomycin Exposure and Ameliorates Its Fibrotic Effects,” Proceedings of the National Academy of Sciences of the United States o…
[cited by applicant]
Pereira, R.F., et al., “Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice,” Proceedings of the National Academy of Sciences of the United Stat…
[cited by applicant]
Pittenger, M. F., for Osiris Therapeutics, “Leaders in Stem Cell Medicine, Applications of Mesenchymal Stem Cells,” Press Release, 2 pages (2001).
[cited by applicant]
Pittenger, M.F., et al., “Multilineage Potential of Adult Human Mesenchymal Stem Cells,” Science 284(5411):143-147, American Association for the Advancement of Science, United States (Apr. 1999).
[cited by applicant]
Prockop, D.J., “Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues,” Science 276(5309):71-74, American Association for the Advancement of Science, United States (Apr. 1997).
[cited by applicant]
Rabe, K.F., et al., “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Gold Executive Summary,” American Journal of Respiratory and Critical Care Medicine, 176(6):53…
[cited by applicant]
Ramasamy, R., et al., “The Immunosuppressive Effects of Human Bone Marrow-derived Mesenchymal Stem Cells Target T Cell Proliferation but Not Its Effector Function,” Cellular Immunology 251(2):131-136, Elsevier, Netherla…
[cited by applicant]
Rasmusson, I., “Immune Modulation by mesenchymal stem cells,” Experimental Cell Research 312:2169-2179, Elsevier, Netherlands (Jul. 2006).
[cited by applicant]
Rayment, E.A., et al., “Concise Review: Mind the Gap: Challenges in Characterizing and Quantifying Cell- and Tissue-based Therapies for Clinical Translation,” Stem Cells (Dayton, Ohio) 28(5):996-1004, Oxford University …
[cited by applicant]
Rojas, M., et al., “Bone Marrow-derived Mesenchymal Stem Cells in Repair of the Injured Lung,” American Journal of Respiratory Cell and Molecular Biology 33(2):145-152, American Thoracic Society, United States (Aug. 200…
[cited by applicant]
Serhan, C.N., et al.,, “Resolution of Inflammation: State of the Art, Definitions and Terms,” The FASEB Journal 21(2):325-332, The Federation, United States (Feb. 2007).
[cited by applicant]
Sherer, Y and Shoenfeld, Y., “Autoimmune Diseases and Autoimmunity Post-bone Marrow Transplantation,” Bone Marrow Transplantation 22:873-881, Stockton Press, United Kingdom (Nov. 1998).
[cited by applicant]
Snowden, J.A., et al., “Long-term Outcome of Autoimmune Disease Following Allogeneic Bone Marrow Transplantation,” Arthritis and Rheumatism 41(3):453-459, Wiley-Blackwell, United States (Mar. 1998).
[cited by applicant]
Thannickal, V.J., et al., “Mechanisms of Pulmonary Fibrosis,” Annual Review of Medicine 55:395-417, Annual Reviews, United States (2004).
[cited by applicant]
Tolar, J., et al., “Concise Review: Hitting the Right Spot With Mesenchymal Stromal Cells,” Stem Cells (Dayton, Ohio) 28(8):1446-1555, Oxford University Press, United Kingdom (Aug. 2010).
[cited by applicant]
Tse, W.T., et al., “Suppression of Allogeneic T-cell Proliferation by Human Marrow Stromal Cells: Implications in Transplantation,” Transplantation 75(3):389-397, Lippincott Williams & Wilkins, United States (Feb. 2003).
[cited by applicant]
Tuli, R., et al., “Characterization of Multipotential Mesenchymal Progenitor Cells Derived from Human Trabecular Bone,” Stem Cells 21(6):681-693, Oxford University Press, United Kingdom (Nov. 2003).
[cited by applicant]
Ullah, I., et al., “Human Mesenchymal Stem Cells-Current Trends and Future Prospective,” Bioscience Reports 35(2):e00191, Springer, United States (Apr. 2015).
[cited by applicant]
Van Laar, J.M., et al., “Adult Stem Cells In the Treatment of Autoimmune Diseases,” Rheumatology (Oxford) 45(10):1187-1193, Oxford University Press, United Kingdom (Oct. 2006).
[cited by applicant]
Vodyanik, M. A., et al., “A mesoderm-derived precursor for mesenchymal stem and endothelial cells,” Cell Stem Cell 7(6):718-729, Cell Press, United States (Dec. 2010).
[cited by applicant]
Wagers, A.J., et al., “Cell Fate Determination From Stem Cells,” Gene Therapy 9(10):606-612, Nature Publishing Group, United Kingdom (May 2002).
[cited by applicant]
Wang, G., et al., “Adult Stem Cells From Bone Marrow Stroma Differentiate Into Airway Epithelial Cells: Potential Therapy for Cystic Fibrosis,” Proceedings of the National Academy of Sciences of the United States of Ame…
[cited by applicant]
Wang, L., et al., “Efficacy and Safety of Mesenchymal Stromal Cells for the Prophylaxis of Chronic Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-analysis of Randomized Contro…
[cited by applicant]
Wang, L.-T., et al., “Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials,” Journal of Biomedical Science 23:76, BioMed Central, United…
[cited by applicant]
Yan, L., et al., “Critical Role of Tumor Necrosis Factor Signaling in Mesenchymal Stem cell-based therapy for autoimmune and inflammatory diseases,” Front Immunol 9:1658, Frontiers Media, Switzerland (Jul. 2018).
[cited by applicant]
Zheng, G., et al., “Treatment of Acute Respiratory Distress Syndrome With Allogeneic Adipose-derived Mesenchymal Stem Cells: A Randomized, Placebo-controlled Pilot Study,” Respiratory Research 15(1):39, BioMed Central L…
[cited by applicant]
Zhou, S. Z., et al., “Adeno-associated Virus 2-Mediated High Efficiency Gene Transfer into Immature and Mature Subsets of Hematopoietic Progenitor Cells in Human Umbilical Cord Blood,” The Journal of Experimental Medici…
[cited by applicant]
Zinöcker, S. and Vaage J.T., “Rat Mesenchymal Stromal Cells Inhibit T Cell Proliferation but Not Cytokine Production Through Inducible Nitric Oxide Synthase,” Frontiers in Immunology 3:62, Frontiers Research Foundation,…
[cited by applicant]
Ziobro, R., et al., “Ceramide Mediates Lung Fibrosis in Cystic Fibrosis,” Biochemical and Biophysical Research Communications 434(4):705-709, Elsevier, United States (May 2013).
[cited by applicant]
Kebriaei, P., et al., “Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease,” Biol Blood Marrow Transplant 15:804-811, Elsevier, Netherlands (2009).
[cited by applicant]
He, X., et al., “Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: a phase 1 clinical trial,” Transl Res 199:52-61, Elsevier, Netherlands (Apr. 2018).
[cited by applicant]
Pereira, T., et al., “MSCs Conditioned Media and Umbilical Cord Blood Plasma Metabolomics and Composition,” PLOS One 9(11):e113769, Public Library of Science, United States (Nov. 2019).
[cited by applicant]
Prasad, A., et al., “Cytokine Detection In Culture Media Containing 10% FBS—A Comparison Of Two Commonly Used Homogeneous High Throughput Assay Technologies,” accessed at https://resources.perkinelmer.com/corporate/cont…
[cited by applicant]
Anonymous, “Newborn Calf Serum S11250: R&D Systems,” accessed at https://www.rndsystems.com/products/newborn-calf-serum_s11250, 4 pages (Aug. 2010).
[cited by applicant]
Liu, S., et al., “Mesenchymal stem cells as a potential therapy for COVID-19,” Stem Cell Research & Therapy 11:169, Springer Nature, Germany (May 2020).
[cited by applicant]
Wilson, J.G., et al., “Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial,” Lancet Respir Med 3(1):24-32, Elsevier, Netherlands (Jan. 2015).
[cited by applicant]
Al-Khawaga, S., et al., “Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients,” Stem Cell Research & Therapy 11:437, Springer Nature, Ge…
[cited by applicant]
Roudsari, P.P., et al., “Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19,” Cell Tissue Bank 21(3):…
[cited by applicant]
Co-pending Application, U.S. Appl. No. 18/711,167, inventor Itescu, S., filed May 17, 2024 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 18/723,204, inventor Itescu, S., filed Dec. 23, 2022 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 19/086,003, inventor Danilkovich, A., et al., filed Mar. 20, 2025 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 19/137,213, inventor Itescu, S., et al., filed Jun. 9, 2025 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 19/137,193, inventor Itescu, S., et al., filed Jun. 9, 2025 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 19/136,677, inventor Itescu, S., et al., filed Jun. 6, 2025 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 19/136,773, inventor Itescu, S., et al., filed Jun. 6, 2025 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 18/869,064, inventor Horst, J., et al., filed Nov. 25, 2025 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 18/872,445, inventor Itescu, S., filed Jun. 8, 2023 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 18/880,992, inventor Itescu, S., et al., filed Jan. 3, 2025 (Not yet Published).
[cited by applicant]
Bich, P.L.T., et al., “Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study.” Stem cell research & therapy 11(1):60, 1-14, Bi…
[cited by applicant]
Cavalli, G., et al., “Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.” The Lancet Rheumatology 3(4): e253-e261, Elsevier Ltd,…
[cited by applicant]
Chen, M., et al., “C-reactive protein mediates the association between leisure-time physical activity and lung function in middle-aged and older adults.” BMC Public Health 20:6, 1-8, BioMed Central (Springer Nature), Un…
[cited by applicant]
Igarashi, T., et al., “Adiponectin and inflammation markers in patients with pneumoconiosis.” Japanese Journal of Occupational and Environmental Medicine (JJOMT) 62:184-188, Japanese Society of Occupational Medicine and…
[cited by applicant]
Kebriaei, P., et al., “A Phase 3 randomized study of remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease.” Biology of Blood and Marrow Transplant…
[cited by applicant]
Landry, A., et al., “Causes and outcomes of markedly elevated C-reactive protein levels.” Canadian Family Physician 63:e316-e323, College of Family Physicians of Canada, Canada (Jun. 2017).
[cited by applicant]
Le, P.T.B., et al., “Umbilical cord derived stem cell (Modulatist™) transplantation for severe chronic obstructive pulmonary disease: a report of two cases.” Biomedical Research and Therapy 3(10):902-909, BioMedPress, V…
[cited by applicant]
Marquez-Curtis, L.A., et al., “Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects.” Cryobiology 71:181-197, Elsevier, United States (Jul. 2015).
[cited by applicant]
Singh, B., et al., “C-Reactive Protein: Clinical Relevance and Interpretation. ” StatPearls [Retrieved from the Internet], https://www.ncbi.nlm.nih. gov/books/NBK441843/, United States (May 2025).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 19/388,629, inventors Danilkovich, A., et al., filed Nov. 13, 2025 (Not yet Published).
[cited by applicant]
Co-pending Application, U.S. Appl. No. 19/521,804, inventor Itescu, S., et al., filed Mar. 20, 2026 (Not yet Published).
[cited by applicant]